NDA 208685 · Ptc Therap
Emflaza
Deflazacort · Oral · Corticosteroid
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Feb 9, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
19
8 Phase 3, 0 recruiting
FAERS reports
6,421
3,256 serious, 311 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 13, 2026.
EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. EMFLAZA is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older ( 1 )
Mechanism: Deflazacort is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 7, 2019 Supplement 3 · Efficacy · priority review OrphanLabelLetter
- Feb 9, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabel
1 products under this application
- EMFLAZA · DEFLAZACORT 22.75MG/ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Deflazacort" as an intervention, any sponsor and status, largest first.
- Omega-3-Based Nutraceutical Supplementation as Adjunctive Therapy in Adults With Otitis Media With Effusion: A Multicenter, Double-Blind, Randomized Placebo-Controlled TrialPivotal-lookingCompleted
Isola Tiberina - Gemelli Isola Hospital, Rome, ItalyAcademic, hospital or other
NCT07721610 · 501 participants · Start Oct 1, 2025 · Primary completion Apr 1, 2026
Drug: Bilastine 20 mg; Placebo Tablet or Capsule and 2 more · For: Otits Media With Effusion
Sites: Roma, Italy
- Finding the Optimum Regimen for Duchenne Muscular DystrophyPivotal-lookingCompleted
University of RochesterAcademic, hospital or other
NCT01603407 · 196 participants · Start Jan 2013 · Primary completion Nov 2019
Drug: Prednisone; Prednisone and 1 more · For: Duchenne Muscular Dystrophy
Sites: Los Angeles, California; Sacramento, California; Washington D.C., District of Columbia · 32 sites in all
- Deflazacort Vs. Prednisolone in Acute-stage ABPAPivotal-lookingActive, not recruiting
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT04227483 · 150 participants · Start Jan 15, 2020 · Primary completion Jul 2025
Drug: Deflazacort; Prednisolone · For: Allergic Bronchopulmonary Aspergillosis
Sites: Chandigarh, India
- Kidney Graft Function Under the Immunosuppression StrategiesPivotal-lookingCompleted
Samsung Medical CenterAcademic, hospital or other
NCT01817322 · 140 participants · Start Jun 2011 · Primary completion Aug 2013
Drug: Standard Dose of Myfortic and Reduced Dose of Myfortic; Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group and 1 more · For: Chronic Renal Disease
- Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)Pivotal-lookingTerminated
Kyntra BioIndustry
NCT04371666 · 98 participants · Start Aug 10, 2020 · Primary completion Feb 13, 2023
Drug: Pamrevlumab; Placebo and 1 more · For: Duchenne Muscular Dystrophy
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 53 sites in all
- Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDPivotal-lookingTerminated
Kyntra BioIndustry
NCT04632940 · 73 participants · Start Mar 3, 2021 · Primary completion Jun 12, 2023
Drug: Pamrevlumab; Placebo and 1 more · For: Duchenne Muscular Dystrophy
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 52 sites in all
PTC TherapeuticsIndustry
NCT02286635 · 58 participants · Start Nov 2014 · Primary completion Dec 2014
Drug: Deflazacort and rifampin; Deflazacort and Clarithromycin · For: Healthy Volunteers
Sites: Tempe, Arizona
Parc de Salut MarAcademic, hospital or other
NCT04791345 · 50 participants (planned) · Start Feb 26, 2021 · Primary completion Feb 26, 2022
Drug: Methylprednisone; Methylprednisone and 3 more · For: Healthy Volunteers
Sites: Barcelona, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- weight increased532
- off label use423
- fall302
- vomiting262
- product dose omission issue260
- no adverse event257
- pyrexia232
- pain231
- drug ineffective220
- headache220
- malaise216
- influenza209
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 26 |
| 2005 | 30 |
| 2006 | 36 |
| 2007 | 32 |
| 2008 | 50 |
| 2009 | 54 |
| 2010 | 65 |
| 2011 | 70 |
| 2012 | 110 |
| 2013 | 124 |
| 2014 | 116 |
| 2015 | 140 |
| 2016 | 125 |
| 2017 | 423 |
| 2018 | 1,227 |
| 2019 | 1,635 |
| 2020 | 312 |
| 2021 | 386 |
| 2022 | 252 |
| 2023 | 331 |
| 2024 | 348 |
| 2025 | 330 |
| 2026 | 199 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Emflaza (Deflazacort)
2024 spending
$15.4M
Beneficiaries
113
1,084 claims
Per beneficiary
$136,433
$435.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,876,991 |
| 2021 | $7,596,448 |
| 2022 | $11,065,608 |
| 2023 | $15,369,330 |
| 2024 | $15,416,876 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
Landfeldt E, Alemán A, Abner S, et al. · J Neuromuscul Dis 2024 · Systematic Review, Meta-Analysis
- Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M, Bushby K, McDermott MP, et al. · JAMA 2022 · Comparative Study, Randomized Controlled Trial
- Corticosteroids for the treatment of Duchenne muscular dystrophy.
Matthews E, Brassington R, Kuntzer T, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacotherapy of Duchenne Muscular Dystrophy.
Hoffman EP · Handb Exp Pharmacol 2020 · Clinical Trial
- Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
McDonald CM, Henricson EK, Abresch RT, et al. · Lancet 2018 · Clinical Trial, Multicenter Study
- Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY, Kuntzer T, Pike M, et al. · Cochrane Database Syst Rev 2004 · Systematic Review
Sponsor: Ptc Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.